Historically drugs was developed and approved in one tissue type. In many cases the same genetic alteration can be driving breast cancer in one patient, and lung cancer in another, opening up for many more treatment options.

We have design combinatorial study with multiple immune therapy targets and checkpoint inhibitors. Design was able to “enroll” 30% of the target population based on the frequency of altered expression. This suggests that effective enrollment can be achieved using OneRNA® whereas enrollment based on mutations can be difficult due to a low population penetrance of a given mutation

Most clinical studies have multiple biomarker inclusion criteria and there is only limited sample material available to test on. OneRNA® detects 20,000 mRNA at the same time with only 2 scrolls of tissue from an FFPE block. 80% of clinical studies fail due to lack of enrollment.

To develop and validate a companion diagnostic in parallel with a drug is like "landing and airplane on the top of a mountain". OneRNA® decrease the risk by turning the biomarker fishing expedition into a math equation which enables you to develop a responder algorithm that meets the study endpoint.

COVID19 demonstrated that we can ge from mRNA code to approved drug in less than 12 month. This is very exciting as it opens up for fast development of the next generation cures and potentially also development of truly individualized mRNA vaccines